Concepedia

Author

Valter Torri

Mario Negri Institute for Pharmacological ResearchORCID

Also Known As

, Alessandro Liberati, Deborah Novelli, G. Tognoni, K. Zaman, L. Clivio, Luca Clivio, M Tomirotti, Michela Cinquini, Norbert Pfeiffer

675

Publications

41.2K

Citations

91

H-Index

185

Concepts

All Affiliations

Mario Negri Institute for Pharmacological ResearchIstituti di Ricovero e Cura a Carattere ScientificoFondazione IRCCS Istituto Nazionale dei TumoriUniversity of MilanIstituto Oncologico Veneto
VT

About

Valter Torri is an author at Mario Negri Institute for Pharmacological Research specializing in medicine, oncology, and radiation oncology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

57

134

12.7K

2

Health Sciences

21

26

2K

3

Nursing

5

5

221

4

Education

1

1

76

5

Humanities

1

1

63

Valter Torri

×

229

Publications

32.1K

Citations

78

H-Index

YearCitations

Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints

Mahesh Parmar, Valter Torri, Lesley Stewart

Statistics in Medicine

1998

4.8K

Lung Adjuvant Cisplatin Evaluation: A Pooled Analysis by the LACE Collaborative Group

Jean‐Pierre Pignon, Hélène Tribodet, Giorgio V. Scagliotti,

Journal of Clinical Oncology

2008

2.6K

Defective Mismatch Repair As a Predictive Marker for Lack of Efficacy of Fluorouracil-Based Adjuvant Therapy in Colon Cancer

Daniel J. Sargent, Silvia Marsoni, Geneviève Monges,

Journal of Clinical Oncology

2010

1.6K

Systematic Pelvic Lymphadenectomy vs No Lymphadenectomy in Early-Stage Endometrial Carcinoma: Randomized Clinical Trial

Pierluigi Benedetti Panici, S. Basile, F. Maneschi,

JNCI Journal of the National Cancer Institute

2008

1.5K

Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial

Mahesh Parmar, Jonathan A. Ledermann, Nicoletta Colombo,

The Lancet

2003

1.2K

Duration of Adjuvant Chemotherapy for Stage III Colon Cancer

Axel Grothey, Alberto Sobrero, Anthony F. Shields,

New England Journal of Medicine

2018

1.1K

Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial

Andrea Sartore‐Bianchi, Livio Trusolino, Cosimo Martino,

The Lancet Oncology

2016

984

Postoperative radiotherapy in non-small-cell lung cancer: systematic review and meta-analysis of individual patient data from nine randomised controlled trials

Sarah Burdett, Mkb Parmar, R L Souhami,

The Lancet

1998

833

COVID-19 in patients with thoracic malignancies (TERAVOLT): first results of an international, registry-based, cohort study

Marina Chiara Garassino, Jennifer G. Whisenant, Li‐Ching Huang,

The Lancet Oncology

2020

621

Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial

Andrés J.M. Ferreri, Kate Cwynarski, Elisa Jacobsen Pulczynski,

The Lancet Haematology

2016

582

Page 1